Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study
T-DXd shows clinical benefit in HER2-expressing MBC, with efficacy influenced by treatment line, HER2 expression, and prior ADC payload type. The prognostic index could aid in personalizing therapy, optimizing patient selection for T-DXd in real-world practice.
Authors
- Haifeng Li (ORCID: https://orcid.org/0000-0002-8883-9470)
- Yunjie Huang (ORCID: https://orcid.org/0000-0003-0636-1256)
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-5414-8049)
- Ditian Shu
- R.C. Chen
- Qixiang Rong (ORCID: https://orcid.org/0000-0001-7719-4243)
- Riqing Huang (ORCID: https://orcid.org/0000-0003-3618-9311)
- Meiting Chen (ORCID: https://orcid.org/0000-0002-7195-1300)
- Zhenhua Yang (ORCID: https://orcid.org/0000-0001-8205-7999)
- Cong Xue (ORCID: https://orcid.org/0009-0007-8702-8696)
- Xiujiao Shen
- Qianyi Liao
- Fei Pan
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Academy of Medical Sciences (GB)
- Sun Yat-sen University (CN)
- Shandong Tumor Hospital (CN)
- Central People's Hospital of Zhanjiang (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Jiangmen Wuyi Traditional Chinese Medicine Hospital (CN)
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine (CN)
- Sun Yat-sen University Cancer Center (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf174
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- National Key Research and Development Program of China
- Sun Yat-sen University Cancer Center